SCHEMBL2231797

SCHEMBL2231797

CCOc1ccc(OCCc2ccc(CN3CCNCC3)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
KDM4E B2RXH2 2/20 0.53
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.49
LTA4H P09960 1/20 0.49
CYP2D6 P10635 1/20 0.49
HRH3 Q9Y5N1 3/20 0.48
CHRM2 P08172 1/20 0.48
CHRM1 P11229 1/20 0.48
ADRA2C P18825 1/20 0.48
CCR2 P41597 1/20 0.48
CXCL12 P48061 1/20 0.48
BLM P54132 1/20 0.48
CXCR4 P61073 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2235571 0.92 TSHR (0.56) TSHRKDM4ERAB9ANPC1ALDH1A1
SCHEMBL1780598 0.91 KDM4E (0.61) TSHRKDM4EMEN1KMT2AHRH3
SCHEMBL2231546 0.89 TSHR (0.62) TSHRRAB9ANPC1ALDH1A1MEN1
SCHEMBL2236728 0.89 SIGMAR1 (0.54) TSHRLTA4HHRH3SIGMAR1SMN1; SMN2
SCHEMBL2294267 0.89 SIGMAR1 (0.54) TSHRLTA4HHRH3SIGMAR1SMN1; SMN2
SCHEMBL2232165 0.89 CXCR4 (0.59) TSHRRAB9ANPC1ALDH1A1MEN1
SCHEMBL2231787 0.89 CXCR4 (0.59) TSHRRAB9ANPC1ALDH1A1MEN1
Hydrochloric Acid SCHEMBL2232210 0.89 CHRM3 (0.50) TSHRKDM4EALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL2233324 0.88 CXCR4 (0.58) TSHRMEN1KMT2ALTA4HHRH3
SCHEMBL2231202 0.87 DRD2 (0.53) TSHRMEN1KMT2ALTA4HHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102791690-B As the disubstituted pyridines derivative of anticarcinogen OTSUKA PHARMACEUTICAL CO.,LTD. (JP) 2015-12-02 CN disclosed
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
EP-2528897-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS Otsuka Pharmaceutical Co., Ltd. (JP) 2012-12-05 EP disclosed
CN-102791690-A Di-substituted pyridine derivatives as anticancers OTSUKA PHARMA CO LTD 2012-11-21 CN disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
WO-2011093524-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 TSHR 2665/4885KDM4E 719/4885RAB9A 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.